A look at a research article about a three-drug approach that enables much lower navitoclax dosing to target senescent and cancer cells, promising a tolerable senolytic strategy.
Key Takeaways
- It is possible that this might make it interesting again, though that ship may have sailed
- There are so very many lines of research and development into novel and better senolytics these days
- Navitoclax has emerged as a promising candidate with both senolytic and antitumor activity